378 related articles for article (PubMed ID: 25608973)
41. Long-term follow-up in osteogenesis imperfecta type VI.
Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
[TBL] [Abstract][Full Text] [Related]
42. Pamidronate Therapy Increases Trabecular Bone Complexity of Mandibular Condyles in Individuals with Osteogenesis Imperfecta.
Pantoja LLQ; Lustosa M; Yamaguti PM; Rosa LS; Leite AF; Figueiredo PTS; Castro LC; Acevedo AC
Calcif Tissue Int; 2022 Mar; 110(3):303-312. PubMed ID: 34677656
[TBL] [Abstract][Full Text] [Related]
43. Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment.
Harada D; Kashiwagi H; Ueyama K; Oriyama K; Hanioka Y; Sakamoto N; Kondo K; Kishimoto K; Izui M; Nagamatsu Y; Yamada H; Tanaka H; Namba N; Seino Y
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1391-1397. PubMed ID: 33031051
[TBL] [Abstract][Full Text] [Related]
44. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
[TBL] [Abstract][Full Text] [Related]
45. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
Weber M; Roschger P; Fratzl-Zelman N; Schöberl T; Rauch F; Glorieux FH; Fratzl P; Klaushofer K
Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
[TBL] [Abstract][Full Text] [Related]
46. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
Zacharin M; Bateman J
J Pediatr Endocrinol Metab; 2002 Feb; 15(2):163-74. PubMed ID: 11874181
[TBL] [Abstract][Full Text] [Related]
47. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
Rauch F; Plotkin H; Zeitlin L; Glorieux FH
J Bone Miner Res; 2003 Apr; 18(4):610-4. PubMed ID: 12674321
[TBL] [Abstract][Full Text] [Related]
48. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
[TBL] [Abstract][Full Text] [Related]
49. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
Zacharin M; Kanumakala S
J Pediatr Endocrinol Metab; 2004 Nov; 17(11):1511-7. PubMed ID: 15570988
[TBL] [Abstract][Full Text] [Related]
50. Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation.
Blouin S; Fratzl-Zelman N; Glorieux FH; Roschger P; Klaushofer K; Marini JC; Rauch F
J Bone Miner Res; 2017 Sep; 32(9):1884-1892. PubMed ID: 28548288
[TBL] [Abstract][Full Text] [Related]
51. Quantitative assessment of mandibular cortical erosion on dental panoramic radiographs for screening osteoporosis.
Muramatsu C; Horiba K; Hayashi T; Fukui T; Hara T; Katsumata A; Fujita H
Int J Comput Assist Radiol Surg; 2016 Nov; 11(11):2021-2032. PubMed ID: 27289239
[TBL] [Abstract][Full Text] [Related]
52. Intravenous pamidronate treatment improves growth in prepubertal osteogenesis imperfecta patients.
Heino TJ; Aström E; Laurencikas E; Sävendahl L; Söderhäll S
Horm Res Paediatr; 2011; 75(5):354-61. PubMed ID: 21304249
[TBL] [Abstract][Full Text] [Related]
53. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta.
Lee YS; Low SL; Lim LA; Loke KY
Eur J Pediatr; 2001 Nov; 160(11):641-4. PubMed ID: 11760017
[TBL] [Abstract][Full Text] [Related]
54. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate.
Munns CF; Rauch F; Zeitlin L; Fassier F; Glorieux FH
J Bone Miner Res; 2004 Nov; 19(11):1779-86. PubMed ID: 15476577
[TBL] [Abstract][Full Text] [Related]
55. Reshaping of vertebrae during treatment with neridronate or pamidronate in children with osteogenesis imperfecta.
Semler O; Beccard R; Palmisano D; Demant A; Fricke O; Schoenau E; Koerber F
Horm Res Paediatr; 2011; 76(5):321-7. PubMed ID: 21952409
[TBL] [Abstract][Full Text] [Related]
56. Two doses of pamidronate in infants with osteogenesis imperfecta.
Senthilnathan S; Walker E; Bishop NJ
Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
[TBL] [Abstract][Full Text] [Related]
58. Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study.
Forin V; Arabi A; Guigonis V; Filipe G; Bensman A; Roux C
Joint Bone Spine; 2005 Jul; 72(4):313-8. PubMed ID: 16038843
[TBL] [Abstract][Full Text] [Related]
59. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
Shapiro JR; McCarthy EF; Rossiter K; Ernest K; Gelman R; Fedarko N; Santiago HT; Bober M
Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
[TBL] [Abstract][Full Text] [Related]
60. Osteogenesis Imperfecta: update on presentation and management.
Cheung MS; Glorieux FH
Rev Endocr Metab Disord; 2008 Jun; 9(2):153-60. PubMed ID: 18404382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
